CIK 0001650664
- Non-accelerated filer
- Smaller reporting company
Editas Medicine, Inc.
Sign in to watch- Ticker
- EDIT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464097528
- Phone
- +1 617-401-9000
- Business address
- 11 HURLEY ST., CAMBRIDGE, MA, 02141
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $89,088
- in 5 filings, $89K under 10b5-1 plans
Net −$89,088. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-09 | Collins Cynthia CEO | Sale | −1,262 | $66.65 | $84K | 43,760 |
| 2020-08-20 | Collins Cynthia CEO | Sale | −1,976 | $36.66 | $72K | 45,022 |
| 2020-02-06 | Collins Cynthia CEO | Grant or award | +15,625 | 46,998 | ||
| 2020-02-06 | Collins Cynthia CEO | Grant or award · Stock Option (right to buy) | +93,750 | 93,750 | ||
| 2019-09-11 | Collins Cynthia CEO | Grant or award | +20,000 | 31,373 | ||
| 2019-09-11 | Collins Cynthia CEO | Grant or award · Stock Option (right to buy) | +500,000 | 500,000 | ||
| 2019-09-11 | Collins Cynthia CEO | Grant or award · Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2019-08-19 | Collins Cynthia CEO | Grant or award | +8,283 | 16,566 | ||
| 2019-08-19 | Collins Cynthia CEO | Sale | −5,193 | $25.83 | $134K | 11,373 |
| 2019-08-06 | Collins Cynthia CEO | Grant or award | +8,283 | 16,566 | ||
| 2019-06-12 | Collins Cynthia Interim CEO | Grant or award · Stock Option (right to buy) | +11,538 | 11,538 | ||
| 2019-01-31 | Collins Cynthia Director | Grant or award · Restricted Stock Units | +8,283 | 8,283 | ||
| 2018-12-06 | Collins Cynthia Director | Grant or award · Stock Option (right to buy) | +23,076 | 23,076 |
Page 1 of 1 · 13 trades